Zymeworks (ZYME) has released an update.
Zymeworks Inc., a biotech firm focused on developing biotherapeutics for hard-to-treat diseases, will release its first quarter 2024 financial results on May 2, 2024, followed by a conference call and webcast. The company, which has submitted a Biologics License Application for its HER2-targeted bispecific antibody zanidatamab, seeks to offer new treatments for various cancers and has multiple global clinical trials underway. Zymeworks continues to expand its pipeline of product candidates and maintains strategic partnerships to leverage its therapeutic platforms.
For further insights into ZYME stock, check out TipRanks’ Stock Analysis page.
